Myositis Specific 11 Antibody Panel

PL-7, PL-12, Mi-2, Ku, EJ, OJ, SRP, U3-RNP, U2-RNP, Jo-1, TIF-1gamma, MDA-5 (CADM-140), NXP-2 (P140), PM/Scl-100, SS-A 52kD, U1-RNP, Myositis Panel 3, Myomarker 3, Myositis Assessor, MyoMarker 3 Profile, Myositis Autoantibodies, nti-p155/140,Nuclear matrix protein,Anti-p140 antibody, JDM, Juvenile dermatomyositis, NuRD Complex, TIF 1-gamma antibody, Necrotizing myopathy, Polymyositis, Dermatomyositis, Anti-synthetase syndrome, Paraneoplastic myositis, Autoimmune myopathy, Myopathy, Transfer RNA synthetase antibody, SRP Signal recognition protein AB, CADM140, Amyopathic dermatomyositis

NOTE: Test includes:
Jo-1 Ab, Pl-7 Ab, Pl-12 Ab, EJ Ab, OJ Ab, SRP Ab, Mi-2 Alpha Ab, Mi-2 Beta Ab, MDA5 Ab, TIF1 Gamma Ab, NXP-2 Ab

Test Codes

EPIC: LAB1232021, Beaker: MYOSITISAB, Quest: 94777

Department

Send Outs

Specimen Collection Criteria

Collect: One Gold-top SST tube. 

Also acceptable: One plain Red-top tube.

Physician Office/Draw Specimen Preparation

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells within four hours of collection. Transfer serum to plastic transport tube and maintain at room temperature (20-26°C or 68-78.8°F) prior to transport.

Preparation for Courier Transport

Transport:  0.5 mL serum, at room temperature (20-26°C or 68-78.8°F). (Minimum: 0.3 mL)

Rejection Criteria

Specimens not collected and processed as indicated.

In-Lab Processing

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells within four hours of collection. Transfer serum to plastic transport tube and maintain at room temperature (20-26°C or 68-78.8°F).
 
Transport:  0.5 mL serum, room temperature (20-26°C or 68-78.8°F). (Minimum: 0.3 mL)

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 7 days
Refrigerated (2-8°C or 36-46°F): 14 days
Frozen (-20°C/-4°F or below): 28 days

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

Laboratory

Sent to Quest Diagnostics, Wood Dale, IL.

Performed

Tuesday – Saturday.
Results available in 3-5 days.

Reference Range

Jo-1 Ab	<11 SI
PL-7 Ab	<11 SI
PL-12 Ab	<11 SI
EJ Ab	<11 SI
OJ Ab	<11 SI
SRP Ab	<11 SI
Mi-2 Alpha Ab	<11 SI
Mi-2 Beta Ab	<11 SI
MDA5 Ab	<11 SI
TIF1 Gamma Ab	<11 SI
NXP-2 Ab	<11 SI

Test Methodology

Line Blot

Clinical Utility

Myositis Specific 11 Antibody Panel - Myositis-specific autoantibodies (MSAs) are highly selective, usually exclusive and are associated with particular clinical phenotypes within the myositis spectrum. Myositis-specific autoantibodies to cytoplasmic enzymes that catalyze the binding of specific amino acids to their cognate tRNA define the anti-synthetase syndrome characterized by myositis and lung inflammation, and include autoantibodies to Jo-1 (antihistidyl-tRNA synthetase), PL-7 (threonyl), PL-12 (alanyl), EJ (glycyl), and OJ (isoleucyl). A further subset of myositis patients is characterized by the presence of autoantibodies directed against the signal recognition particle (SRP). Autoantibodies to Mi-2 (Mi-2/nucleosome remodeling and deacetylase (NuRD) complex) are detected in patients with hallmark dermatomyositis features. Autoantibody to a cytoplasmic 140-kDa protein, melanoma-differentiation associated gene 5 (MDA5), also known as anti-CADM140, identified patients with clinically amyopathic dermatomyositis (CADM) and rapidly progressive lung disease. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF-1 y), a p155/140 nuclear protein involved in cellular differentiation, have been reported in adult and juvenile dermatomyositis; in adults, it is associated with malignancy. Autoantibodies to nuclear matrix protein NXP-2, another 140-kDa protein, is found in juvenile dermatomyositis (JDM). Anti-TIF-1 y and anti-NXP-2, two novel serological subsets in JDM, occur collectively in >40% of children and appear to identify those with more severe disease.

CPT Codes

86235 x5, 84128 x6.

Contacts

Last Updated

3/4/2026